ADMA Biologics Inc $ADMA Shares Acquired by Sachem Head Capital Management LP

Sachem Head Capital Management LP raised its holdings in shares of ADMA Biologics Inc (NASDAQ:ADMA) by 27.0% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 11,375,000 shares of the biotechnology company’s stock after acquiring an additional 2,415,000 shares during the period. ADMA Biologics makes up about 4.9% of Sachem Head Capital Management LP’s portfolio, making the stock its 10th biggest position. Sachem Head Capital Management LP’s holdings in ADMA Biologics were worth $207,480,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also bought and sold shares of the business. MML Investors Services LLC lifted its stake in ADMA Biologics by 15.2% during the 4th quarter. MML Investors Services LLC now owns 29,052 shares of the biotechnology company’s stock valued at $530,000 after acquiring an additional 3,829 shares during the period. Mariner LLC lifted its stake in ADMA Biologics by 82.3% during the 4th quarter. Mariner LLC now owns 69,942 shares of the biotechnology company’s stock valued at $1,276,000 after acquiring an additional 31,569 shares during the period. Next Century Growth Investors LLC lifted its stake in ADMA Biologics by 178.3% during the 4th quarter. Next Century Growth Investors LLC now owns 1,100,773 shares of the biotechnology company’s stock valued at $20,078,000 after acquiring an additional 705,217 shares during the period. Fieldview Capital Management LLC lifted its stake in ADMA Biologics by 7.3% during the 4th quarter. Fieldview Capital Management LLC now owns 21,708 shares of the biotechnology company’s stock valued at $396,000 after acquiring an additional 1,486 shares during the period. Finally, Kennedy Capital Management LLC lifted its stake in ADMA Biologics by 24.5% during the 4th quarter. Kennedy Capital Management LLC now owns 677,600 shares of the biotechnology company’s stock valued at $12,359,000 after acquiring an additional 133,427 shares during the period. 75.68% of the stock is currently owned by institutional investors and hedge funds.

ADMA Biologics Stock Performance

ADMA opened at $8.21 on Monday. The company has a debt-to-equity ratio of 0.51, a current ratio of 6.95 and a quick ratio of 3.93. The firm has a fifty day moving average price of $9.17 and a 200 day moving average price of $14.12. ADMA Biologics Inc has a 1 year low of $7.21 and a 1 year high of $21.53. The stock has a market cap of $1.90 billion, a P/E ratio of 12.07 and a beta of 0.73.

ADMA Biologics (NASDAQ:ADMA) last posted its earnings results on Wednesday, May 6th. The biotechnology company reported $0.19 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.19. ADMA Biologics had a net margin of 32.43% and a return on equity of 39.98%. The firm had revenue of $114.49 million during the quarter, compared to analysts’ expectations of $139.98 million. During the same period in the previous year, the business posted $0.11 EPS. The business’s revenue was down .3% compared to the same quarter last year. Equities research analysts anticipate that ADMA Biologics Inc will post 0.82 earnings per share for the current year.

ADMA Biologics News Roundup

Here are the key news stories impacting ADMA Biologics this week:

• Positive Sentiment: Raymond James upgraded ADMA Biologics to moderate buy and set a $21 price target, signaling meaningful upside versus recent trading levels.
• Neutral Sentiment: Several law firms reiterated that investors in ADMA Biologics can seek lead-plaintiff status in the already filed class action, with the deadline set for August 10, 2026. Article Title
• Neutral Sentiment: The company continues to face a broad set of investor-rights notices and duplicate lawsuit solicitations from firms including Rosen, Kirby McInerney, Faruqi & Faruqi, and others, keeping the stock in litigation-focused headlines. Article Title
• Negative Sentiment: Multiple class actions allege ADMA Biologics misrepresented its operations and revenue quality, including channel-stuffing claims and internal-control issues, which raises legal and reputational risk for shareholders.

Analyst Upgrades and Downgrades

Several analysts have commented on the stock. Wall Street Zen cut shares of ADMA Biologics from a “buy” rating to a “hold” rating in a research note on Monday, May 4th. Cantor Fitzgerald restated a “neutral” rating on shares of ADMA Biologics in a research note on Thursday, March 26th. Zacks Research cut shares of ADMA Biologics from a “hold” rating to a “strong sell” rating in a research note on Tuesday, May 26th. Raymond James Financial initiated coverage on shares of ADMA Biologics in a research note on Wednesday. They issued an “outperform” rating and a $21.00 target price for the company. Finally, Mizuho decreased their target price on shares of ADMA Biologics from $24.00 to $20.00 and set an “outperform” rating for the company in a research note on Thursday, May 7th. Three research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $19.67.

Insider Activity

In other news, Director Jerrold B. Grossman bought 12,500 shares of the firm’s stock in a transaction that occurred on Monday, May 11th. The stock was purchased at an average cost of $8.01 per share, for a total transaction of $100,125.00. Following the purchase, the director directly owned 513,884 shares in the company, valued at approximately $4,116,210.84. This trade represents a 2.49% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 3.90% of the stock is currently owned by corporate insiders.

ADMA Biologics Profile

ADMA Biologics, Inc is a biopharmaceutical company headquartered in Ramsey, New Jersey, that focuses on the development, manufacturing and commercialization of specialty plasma-derived biologics for the treatment of primary immunodeficiency and infectious diseases. Leveraging an integrated model that spans plasma collection, fractionation, formulation and fill-finish operations, ADMA Biologics aims to address unmet needs in immune-compromised and high-risk patient populations.

The company’s marketed product portfolio includes BIVIGAM, a human immunoglobulin intravenous (IGIV) therapy approved by the U.S.